Click on image to view larger version.

Figure 1 Cumulative distribution plot of the incremental cost-effectiveness ratio for embolic protection compared with conventional treatment based on the Saphenous Vein Graft Angioplasty Free of Emboli Randomized trial (SAFER) results. As indicated by the arrow, 97.3% of the bootstrapped cost-effectiveness ratios were <$40,000 per year of life gained.